Navigation Links
MabVax Therapeutics Receives $1,750,000 Small Business Innovation Research Contract Award From The National Cancer Institute To Support Development of Novel Pancreatic Cancer Diagnostic Imaging Agent
Date:9/24/2013

SAN DIEGO, Sept. 24, 2013 /PRNewswire/ -- MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of innovative vaccine and antibody based therapies to treat cancer, announces that it has received Contract No. HHSN261201300060C from the National Cancer Institute, National Institutes of Health, under the Small Business Innovation Research Technology Program (SBIR).  The award is in the amount of $1,750,000 over the next three years subject to satisfactory progress and continued availability of funds in the SBIR program.  The grant will support development of a novel positron emission tomography (PET) imaging product for the diagnosis, staging, and treatment assessment of pancreatic cancer.  The product, an antibody fragment linked to a radioactive tracer, is based on the company's discovery of a human antibody designated 5B1 that binds to a cancer antigen expressed on pancreatic cancer.

Pancreatic ductal adenocarcinoma (PDAC or pancreatic cancer) is a leading cause of cancer-related mortality worldwide primarily due in part to late stage diagnosis stemming from the lack of an early diagnostic screening tool.  It is the fourth most common cause of cancer-related death in the United States with 36,800 deaths reported in 2010.  Five-year relative survival rates have changed very little in the last 40 years.

The carbohydrate antigen sialyl-Lewisa (sLea) is expressed on pancreatic colon and stomach cancers cells at high levels where it is used as a tumor marker and presents an attractive molecular target.  sLea  facilitates tumor adhesion and extravasation that are key events for tumor metastasis, and thus presents a marker for the very cells that cause cancer recurrence.  Increased sLea expression on tumors is correlated with poor clinical outcome.  MabVax Therap
'/>"/>

SOURCE MabVax Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MabVax Therapeutics Closes $5.25 Million Financing with Numoda Capital Innovations, Burrill Capital Fund IV, and RTP Venture Fund
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
4. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
5. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
6. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
7. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
8. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
9. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
10. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
11. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015  By looking at ... to distinguish between two very different conditions that ... Theodore Henderson , MD, PhD., a ... cases, this study can help the ... therefore treatment options, for Post-Traumatic Stress Disorder (PTSD) ...
(Date:5/4/2015)... 2015  CytRx Corporation (Nasdaq: CYTR ), ... oncology, today announced an interim analysis from its ... aldoxorubicin with either gemcitabine or ifosfamide. Both studies ... escalating doses of aldoxorubicin. The combinations appear to ... dose level of aldoxorubicin (170 mg/m2), impressive tumor ...
(Date:5/4/2015)... CONCORD, N.H. , May 4, 2015 /PRNewswire/ ... creating analytic and technology solutions to improve healthcare ... Bedford Nursing & Rehabilitation Center (BNRC) use ... monitoring platform to improve the quality and lower ... analytics platform integrates clinical, outcomes, claims and utilization ...
Breaking Medicine Technology:New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 2New Medical Research Shows Brain Imaging Can Now Help Doctors Differentiate Between PTSD and Traumatic Brain Injuries 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 2Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 3
... 2010 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: ... developer, manufacturer and seller of medicine and drugs in the ... four members of its board of directors and the subsequent ... Mr. Lijun Fan, Mr. Zhaohui Li, and Mr. Jun Lu ...
... Dec. 21, 2010 Silence Therapeutics plc (AIM: SLN) ... dedicated to the discovery, development and delivery of targeted, ... serious diseases, today provides a year-end update on trading ... Silence Therapeutics, comments: "2010 has been an exciting ...
Cached Medicine Technology:Lotus Pharmaceuticals Announces Change of Directors 2Lotus Pharmaceuticals Announces Change of Directors 3Lotus Pharmaceuticals Announces Change of Directors 4Silence Therapeutics Provides Year-end Update 2Silence Therapeutics Provides Year-end Update 3
(Date:5/4/2015)... SACRAMENTO, Calif. (PRWEB) May 04, 2015 ... Permanente Medical Group today launched a new initiative ... building the next generation of physicians committed to ... Estudiantes Para Ser Medicos, or Preparing Students to ... multi-faceted initiative that will provide scholarships, mentorship and ...
(Date:5/4/2015)... Atlanta, Georgia (PRWEB) May 04, 2015 Each ... the country to raise funds and awareness for breast cancer. ... Plastic Surgery will be featured as the entertainment sponsor for ... the Cure” on May 9 at the Lenox Square Mall. ... year’s Atlanta race, and to raise $1.2 million. Perimeter Plastic ...
(Date:5/4/2015)... R.I. (PRWEB) May 04, 2015 Johnson & ... $40 million engineering and science academic center on Wednesday, April ... the ground for land made available by the re-alignment of ... the corner of Friendship and Chestnut streets in Providence, is ... built on a parcel of land the university purchased in ...
(Date:5/4/2015)... 04, 2015 The Lymphoma Research Foundation ... to funding innovative lymphoma research and serving the lymphoma ... initiatives and patient services – is set to host ... Farms in West Orange, NJ on June 1, 2015. ... innovative research programs through LRF. , This year, the ...
(Date:5/4/2015)... 04, 2015 Baptist Medical Center ... Association’s Get With The Guidelines®-Stroke Gold Plus Quality ... Roll. The award recognizes the hospital’s commitment and ... most appropriate treatment according to nationally recognized, research-based ... To receive the Gold Plus Quality Achievement Award, ...
Breaking Medicine News(10 mins):Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 3Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 4Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 5Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 2Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 3Health News:Baptist Medical Center Jacksonville Receives Top Honor for Stroke Care 4
... a strain of HIV that is extremely hard to treat, ... ,At least two types of HIV drugs don't work ... from Public Health — Seattle & King County said Thursday. ... the gay community is at highest risk," said Dr. Bob ...
... genes from an ancient wheat variety have led to a ... a recent set of papers published in the journal Plant ... and Nax2. The genes work by excluding salt from different ... from the leaves. The discovery of the two genes is ...
... has continued to decrease since the early 1990s, the rate ... percent higher in African American women than in white men ... ,However, the disparity among men has narrowed over ... African Americans than whites. These data appear in the newly ...
... increase in allergic reactions among people who use hair dye, ... Teenagers appear to be more susceptible, as they are seen ... ,The common allergic reactions are rashes, facial swelling and ... ,Now researchers are pressing for a wider debate about ...
... being tired or exhausted, people should take these complaints ... or even death, says a University of Alberta researcher ... of A professor from the Faculty of Nursing, argues ... and that recognizing those distinctions will help health-care workers ...
... clinical practice guidelines for diagnosis and management of venous ... causes clotting in the veins. ,Key elements ... prediction rules to establish pretest probability of deep vein ... testing and the utility of various diagnostic tools such ...
Cached Medicine News:Health News:New HIV Threat Found in King County 2Health News:Ancient Genes Used to Produce Salt-Tolerant Wheat 2Health News:Cancer Death Rates High in African-Americans 2Health News:Take Fatigue Seriously - Says Researcher 2Health News:Take Fatigue Seriously - Says Researcher 3Health News:New Guidelines for Diagnosis of Venous Thromboembolism 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: